---
title: "Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287438410.md"
description: "On May 21, 2026, Immix Biopharma, Inc. disclosed the pricing details of its underwritten registered offering. The offering consists of 16,778,524 shares of common stock priced at $8.94 per share for a total of $150 million in gross proceeds for Immix. The offering is scheduled to conclude around May 22, 2026, pending the fulfillment of standard closing prerequisites."
datetime: "2026-05-23T18:12:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287438410.md)
  - [en](https://longbridge.com/en/news/287438410.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287438410.md)
---

# Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock

On May 21, 2026, Immix Biopharma, Inc. disclosed the pricing details of its underwritten registered offering. The offering consists of 16,778,524 shares of common stock priced at $8.94 per share for a total of $150 million in gross proceeds for Immix. The offering is scheduled to conclude around May 22, 2026, pending the fulfillment of standard closing prerequisites.

### Related Stocks

- [IMMX.US](https://longbridge.com/en/quote/IMMX.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

- [Immix Biopharma (NASDAQ:IMMX) Coverage Initiated at Needham & Company LLC](https://longbridge.com/en/news/293471721.md)
- [Immix Biopharma posts corporate presentation highlighting NXC-201 CAR-T in relapsed/refractory AL amyloidosis](https://longbridge.com/en/news/291677993.md)
- [Immix Biopharma publishes corporate presentation highlighting NXC-201 CAR-T in relapsed/refractory AL amyloidosis](https://longbridge.com/en/news/290084904.md)
- [Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions](https://longbridge.com/en/news/290233235.md)
- [Immix Biopharma Prices $150 Million Underwritten Offering To Advance NXC-201 Program](https://longbridge.com/en/news/287220519.md)